West Oak Capital’s Pacira BioSciences PCRX Stock Holding History

West Oak Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$15K	–	353
2022 Q1	$15K	Buy	+200	New	+$13.3K	0.01%	239

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

West Oak Capital's PCRX Position: Q2 2022 in Review

West Oak Capital sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 200 shares — an estimated $15K sold.

West Oak Capital first reported a position in PCRX in Q1 2022 and held it in 1 quarter. The position peaked at $15K in Q1 2022. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

West Oak Capital reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
West Oak Capital sold 200 Pacira BioSciences shares in Q2 2022, an estimated $15K.
West Oak Capital first reported a position in Pacira BioSciences in Q1 2022 and held it in 1 quarter.
West Oak Capital's Pacira BioSciences position peaked at $15K in Q1 2022.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on West Oak Capital's 13F filing for Q2 2022, filed 11 Jul 2022.